Aap Implantate AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
aap Implantate AG Issues Q4 2013 Sales And EBITDA Guidance
aap Implantate AG announced that for the fourth quarter of 2013, the management board forecasts sales in the range of EUR10.5 million to EUR11.6 million and an EBITDA of EUR1.3 million to EUR1.7 million. Sales and profitability will be mainly driven by sales of trauma products, especially LOQTEQ(R), and as previously announced, bone cement and cementing devices.
Latest Developments for Aap Implantate AG
- aap Implantate AG closing of European Medical Contract Manufacturing B.V. divestment
- aap Implantate AG divests contract manufacturing business to private equity company
- aap Implantate AG issues Sales and EBITDA guidance for Q1 2014 and fiscal 2014 in line with analysts estimates
- aap Implantate AG Confirms FY 2013 Guidance
- Share this
- Digg this